TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37604637

Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics administered within 24 hours
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Multiple doses of prophylactic antibiotics administered within 24 hours
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Multiple doses of prophylactic antibiotics
Number of subjects: 20000
Study: 37604649

Group type: COMPARATOR
Intervention: Rural population
Number of subjects: 8452
Study: 37604662

Group type: COMPARATOR
Intervention: Metoclopramide + 4 mg dexamethasone
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Metoclopramide + 16 mg dexamethasone
Number of subjects: 209

Group type: COMPARATOR
Intervention: Low-dose dexamethasone (4 mg)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (16 mg)
Number of subjects: 209
Study: 37604693

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37604857

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 532
Study: 37604981

Group type: EXPERIMENTAL
Intervention: Glasdegib plus intensive chemotherapy (cytarabine and daunorubicin)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Glasdegib plus non-intensive chemotherapy (azacitidine)
Number of subjects: 729

Group type: COMPARATOR
Intervention: Glasdegib
Number of subjects: 729
Study: 37604988

Group type: EXPERIMENTAL
Intervention: FUS-MB treatment delivered before 1st and 5th fractions of RT (within 1 hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fractionated RT (5 or 10 fractions)
Number of subjects: 8
Study: 37605035

Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37605068

Group type: EXPERIMENTAL
Intervention: VWF-Ag
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: VWF-N
Number of subjects: 229

Group type: COMPARATOR
Intervention: ADAMTS13 activity
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: VWF cleavage
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: VWF activity
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: VWF-Ag levels and VWF-N
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: ADAMTS13-Act
Number of subjects: 229
Study: 37605150

Group type: EXPERIMENTAL
Intervention: First-line ART with 100% adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line ART with side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line ART with opportunistic infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High HIV viral load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CD4 count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of comorbidities
Number of subjects: 0
Study: 37605151

Group type: EXPERIMENTAL
Intervention: Dutch Client Satisfaction with Device (D-CSD)
Number of subjects: 76
Study: 37605193

Group type: EXPERIMENTAL
Intervention: Quadrant scaling and root-planing (Q-SRP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 46
Study: 37605227

Group type: EXPERIMENTAL
Intervention: ADSC-CM combined with 5% minoxidil
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaCl 0.9% as placebo combined with 5% minoxidil
Number of subjects: 0
Study: 37605251

Group type: EXPERIMENTAL
Intervention: Anatomical ablation using multiple RF applicators
Number of subjects: 55
Study: 37605274

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 0
Study: 37605542

Group type: EXPERIMENTAL
Intervention: Regular consumption of grapes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37605636

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1654
Study: 37606172

Group type: COMPARATOR
Intervention: MHFA training
Number of subjects: 22604
Study: 37606364

Group type: EXPERIMENTAL
Intervention: Oral lipid nanocrystal (LNC) amphotericin B + flucytosine (1.8 g/d for 2 weeks, then 1.2 g/d for 6 weeks)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oral lipid nanocrystal (LNC) amphotericin B with IV loading doses + flucytosine
Number of subjects: 121

Group type: COMPARATOR
Intervention: IV amphotericin + flucytosine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison of adverse events between LNC amphotericin and IV amphotericin
Number of subjects: 121
Study: 37606495

Group type: EXPERIMENTAL
Intervention: luspatercept (BMS-986346/ACE-536)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 37606572

Group type: EXPERIMENTAL
Intervention: 8-mm covered TIPS
Number of subjects: 100

Group type: COMPARATOR
Intervention: EVL plus propranolol
Number of subjects: 100
Study: 37606606

Group type: EXPERIMENTAL
Intervention: CBD daily in cycle 1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 37606641

Group type: EXPERIMENTAL
Intervention: Regorafenib (starting dose 72 mg/m2/day) with vincristine (1.5 mg/m2 on days 1 and 8) and irinotecan (50 mg/m2 on days 1-5)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regorafenib (MTD/RP2D of 82 mg/m2 in sequential schedule)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regorafenib combined with vincristine and irinotecan
Number of subjects: 21
Study: 37606672

Group type: EXPERIMENTAL
Intervention: EC-IC bypass surgery plus medical therapy (surgical group; n=161)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Medical therapy alone (medical group; n=163)
Number of subjects: 324
Study: 37606852

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 367
Study: 37606856

Group type: EXPERIMENTAL
Intervention: Neurotropic infections (viral, bacterial, protozoal) assessed through serology testing in patients treated with immune checkpoint inhibitors (ICI).
Number of subjects: 61

Group type: COMPARATOR
Intervention: Neurotropic infections in the Dutch/Australian cohort (11 patients with neurological irAEs) compared to 27 control patients.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Neurotropic infections in the German cohort (13 patients with neurological irAEs) compared to 10 control patients.
Number of subjects: 61
Study: 37606897

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37606907

Group type: EXPERIMENTAL
Intervention: Robotic-assisted techniques for graft hysterectomy after uterus transplantation
Number of subjects: 0
Study: 37606923

Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1221
Study: 37606965

Group type: EXPERIMENTAL
Intervention: Focused-PPC model of care
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 192
Study: 37606979

Group type: EXPERIMENTAL
Intervention: Web-based PROM symptom monitoring program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clinical alerts triggered by the PROM monitoring system
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calls in response to alerts
Number of subjects: 39
Study: 37607074

Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 855
Study: 37607093

Group type: EXPERIMENTAL
Intervention: Direct admission to specialized trauma center
Number of subjects: 970

Group type: COMPARATOR
Intervention: Transfer from intermediate hospital
Number of subjects: 970
Study: 37607096

Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T Cell Manufacturing using CliniMACS Prodigy
Number of subjects: 0
Study: 37607203

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 30 minutes each morning for 3-4 weeks
Number of subjects: 26
Study: 37607311

Group type: EXPERIMENTAL
Intervention: Interactive workshops and written handouts
Number of subjects: 120

Group type: COMPARATOR
Intervention: Written handouts only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (workshop and written handouts)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phone interviews of workshop group participants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Workshops
Number of subjects: 120
Study: 37607323

Group type: EXPERIMENTAL
Intervention: Self-reported data via annual follow-up online questionnaires
Number of subjects: 11314

Group type: EXPERIMENTAL
Intervention: Data Warehouse Procedural Process (DWPP)
Number of subjects: 11314

Group type: COMPARATOR
Intervention: Self-report only
Number of subjects: 11314

Group type: COMPARATOR
Intervention: DWPP alone
Number of subjects: 11314

Group type: EXPERIMENTAL
Intervention: Combined self-reported data with EHR data from a health system data warehouse registry
Number of subjects: 11314
Study: 37607422

Group type: COMPARATOR
Intervention: Intensive Lifestyle (ILS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo (PLB)
Number of subjects: 0
Study: 37607457

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Non-HCT treatment
Number of subjects: 309
Study: 37607644

Group type: EXPERIMENTAL
Intervention: Propylene glycol-free melphalan (PGF-Mel) at 140 to 200 mg/m²
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propylene glycol-free melphalan (PGF-Mel)
Number of subjects: 28
Study: 37607661

Group type: EXPERIMENTAL
Intervention: BGF MDI with hydrofluoroolefin-1234ze (HFO)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BGF MDI with hydrofluorocarbon-152a (HFC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: BGF MDI with hydrofluoroalkane-134a (HFA)
Number of subjects: 47
Study: 37607748

Group type: EXPERIMENTAL
Intervention: Full next-generation sequencing (NGS) genetic panel
Number of subjects: 335

Group type: COMPARATOR
Intervention: Partial genetic panel offered by the Quebec Ministère de la Santé et des Services sociaux (MSSS)
Number of subjects: 335
Study: 37607780

Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR) 900 mg for the first 3 doses followed by 300 mg every 4 weeks
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab basic regimen (BR) 300 mg every 4 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab IR
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab BR
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Anifrolumab IR and BR
Number of subjects: 147
Study: 37607787

Group type: EXPERIMENTAL
Intervention: Comprehensive multicomponent exercise programme
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Simple multicomponent exercise programme (walking and sit-to-stand exercises)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 37607809

Group type: EXPERIMENTAL
Intervention: Tapering TNFi to discontinuation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Stable TNFi
Number of subjects: 84
Study: 37608129

Group type: EXPERIMENTAL
Intervention: Plasma copper (Cu) levels
Number of subjects: 34
Study: 37608248

Group type: EXPERIMENTAL
Intervention: Neurofibromatosis type 1 (NF1) group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neurofibromatosis type 1 (NF1) group during working memory task
Number of subjects: 16

Group type: COMPARATOR
Intervention: Typically developing control group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Typically developing control group during working memory task
Number of subjects: 16
Study: 37608269

Group type: COMPARATOR
Intervention: 20 ml group (ESB with 10 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 7 ml of saline 0.9%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 ml group (ESB with 15 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 12 ml of saline 0.9%)
Number of subjects: 50
Study: 37608287

Group type: EXPERIMENTAL
Intervention: Invimestrocel plus standard treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study: 37608315

Group type: EXPERIMENTAL
Intervention: Amantadine administered intravenously for five days at a dosage of 100 mg bid.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Amantadine (if non-responders, dosage doubled from day three to five).
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Amantadine treatment.
Number of subjects: 43
Study: 37608321

Group type: EXPERIMENTAL
Intervention: Loss of cervical lordosis group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal cervical lordosis group
Number of subjects: 57
Study: 37608354

Group type: EXPERIMENTAL
Intervention: Self-adjusting compression garment (ReadyWrap®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of compressive bandaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of compressive mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of compressive bandaging and compressive mesh
Number of subjects: 0
Study: 37608391

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 710
Study: 37608389

Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention, practiced at home with a 45-min video, at least 3 times per week for 12 weeks.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention
Number of subjects: 69
Study: 37608390

Group type: EXPERIMENTAL
Intervention: Compliance through reduction (via relocation and reduction in personal smoking) and cessation intervention
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Compliance through resident endorsement intervention
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: A plus B (both interventions)
Number of subjects: 500000

Group type: COMPARATOR
Intervention: NYCHA standard approach
Number of subjects: 500000
Study: 37608471

Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg)
Number of subjects: 30
Study: 37608473

Group type: EXPERIMENTAL
Intervention: Multicomponent health care intervention
Number of subjects: 225
Study: 37608568

Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises (CSEs) in addition to conventional exercises (CEs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional exercises (CEs)
Number of subjects: 25
Study: 37608590

Group type: EXPERIMENTAL
Intervention: Weight loss condition
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study: 37608909

Group type: EXPERIMENTAL
Intervention: Pressure biofeedback-guided DCFM strength training and conventional treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual therapy and conventional treatment
Number of subjects: 60
Study: 37609003

Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane emulsion (DDFPe) administered via intravenous infusion at doses of 0.05, 0.10, or 0.17 mL/kg while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks) along with standard-of-care chemotherapy (temozolomide).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane emulsion (DDFPe) administered at 0.1 mL/kg dose level.
Number of subjects: 11
Study: 37609269

Group type: COMPARATOR
Intervention: Step Activity Monitoring (SAM)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combined intervention (FAST+SAM)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: High-intensity walking intervention (FAST)
Number of subjects: 250
Study: 37609318

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37609358

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous treprostinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose subcutaneous treprostinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of high-dose vs low-dose treprostinil
Number of subjects: 0
Study: 37609651

Group type: EXPERIMENTAL
Intervention: First-line anti-seizure medications (ASMs) as substitution therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Second-line anti-seizure medications (ASMs)
Number of subjects: 102
Study: 37609698

Group type: EXPERIMENTAL
Intervention: Prasugrel only at the start of PCI
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cangrelor plus prasugrel concomitantly at the start of PCI
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cangrelor at the start of PCI plus prasugrel at the end of infusion
Number of subjects: 77
Study: 37609714

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy
Number of subjects: 0
Study: 37609778

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and endocrine therapy (no other systemic therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ki67 immunohistochemistry assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IKWG-recommended scoring method
Number of subjects: 0
Study: 37609806

Group type: EXPERIMENTAL
Intervention: Social determinants of health (SDoH)
Number of subjects: 0
Study: 37609931

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 5661

Group type: COMPARATOR
Intervention: ramipril
Number of subjects: 5661
Study: 37609948

Group type: COMPARATOR
Intervention: Moderate chocolate consumption (Mod-Ch) >1-6 servings/week
Number of subjects: 3931

Group type: EXPERIMENTAL
Intervention: No/Low chocolate consumption (No/Low-Ch) ≤1 servings/week
Number of subjects: 3931

Group type: COMPARATOR
Intervention: High chocolate consumption (High-Ch) >6 servings/week
Number of subjects: 3931
Study: 37609981

Group type: EXPERIMENTAL
Intervention: Carotid plaque score
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Carotid plaque score cutoff >3
Number of subjects: 3650
Study: 37610332

Group type: EXPERIMENTAL
Intervention: Nurse-led package of care (non-pharmacological treatment)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Overall study feasibility
Number of subjects: 208
Study: 37610383

Group type: EXPERIMENTAL
Intervention: Optimized attachments (O)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal attachments (H)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal incisally-beveled attachments (HIB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal gingivally-beveled attachments (HGB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Horizontal attachments (H, HIB, HGB combined)
Number of subjects: 40
Study: 37610533

Group type: EXPERIMENTAL
Intervention: Mirikizumab 50-1000 mg intravenously every 4 weeks as induction treatment
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg subcutaneously every 4 or 12 weeks as maintenance treatment
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Mirikizumab (general)
Number of subjects: 1362
Study: 37610564

Group type: EXPERIMENTAL
Intervention: CD exclusion diet plus partial enteral nutrition for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 21
Study: 37610727

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 178
Study: 37610731

Group type: EXPERIMENTAL
Intervention: Precision Strategy (PS)
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Usual Testing (UT)
Number of subjects: 2103
Study: 37610747

Group type: EXPERIMENTAL
Intervention: Nonspecific psychotherapy (32 sessions)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disorder-specific psychotherapy (32 sessions)
Number of subjects: 254
Study: 37610757

Group type: EXPERIMENTAL
Intervention: Balloon inflation in the cardiac coronary sinus (CS)
Number of subjects: 20
Study: 37610768

Group type: EXPERIMENTAL
Intervention: Deferred testing
Number of subjects: 422

Group type: COMPARATOR
Intervention: Usual testing
Number of subjects: 422
Study: 37610800

Group type: EXPERIMENTAL
Intervention: Increased standing (STAND) via smartphone app prompts to stand for an additional 6 minutes each hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased moving (MOVE) via smartphone app prompts to move for an additional 6 minutes each hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased standing (STAND)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased moving (MOVE)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased standing (STAND) and Increased moving (MOVE)
Number of subjects: 15
Study: 37610803

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib (D+T)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Carboplatin plus Vincristine (C+V)
Number of subjects: 110
Study: 37610821

Group type: EXPERIMENTAL
Intervention: Video intervention (animated videos)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Text-only intervention
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Older age (36-75 years)
Number of subjects: 1056
Study: 37610927

Group type: EXPERIMENTAL
Intervention: Postnatal breastfeeding education
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no postnatal breastfeeding education)
Number of subjects: 76
Study: 37611007

Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation using sidestream capnography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Closed-loop ventilation using mainstream capnography
Number of subjects: 80
Study: 37611121

Group type: EXPERIMENTAL
Intervention: Divarasib (GDC-6036) administered orally once daily at doses ranging from 50 to 400 mg
Number of subjects: 137
Study: 37611156

Group type: EXPERIMENTAL
Intervention: Busulfan 80 mg/m2 as outpatients on days -20 and -13 before transplant, Fludarabine 40 mg/m2 on days -6 to -3, busulfan dosed to achieve a target AUC of 20,000 mol/min for the whole course.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Busulfan regimen
Number of subjects: 78